SAN DIEGO--(

圣地亚哥--(

BUSINESS WIRE

商业热线

)--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “REVB.” The CUSIP number for the common stock following the reverse stock split will be 76135L606..

)--启示生物科学公司（NASDAQ:REVB）（“公司”或“启示”）今天宣布，2025年1月28日，经2025年1月17日举行的股东特别会议批准，公司将对其普通股实施16股1股反向分割。反向股票分割将于2025年1月28日上午生效，该公司的普通股将在同一天交易开始时以分割后的方式在现有交易符号“REVB”下进行交易。反向股票分割后的普通股CUSIP编号为76135L606。。

The reverse stock split is intended to increase the market price per share of the Company’s common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company’s warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company’s equity incentive plans..

反向股票分割旨在提高公司普通股每股的市场价格，以重新符合纳斯达克资本市场的最低出价持续上市要求。将按比例调整公司认股权证、限制性股票单位奖励、股票期权的转换和行权价格，以及根据公司股权激励计划发行和可发行的股票数量。。

Revelation Bioscience Inc. on January 21st announced the start of its Prime Phase 1b clinical study of Gemini in CKD patients. The dosing to commence in Mid-February 2025 and Topline data expected Mid-Year. For more information on Revelation, please visit

。剂量将于2025年2月中旬开始，预计年中会有顶线数据。有关启示的更多信息，请访问

www.RevBiosciences.com

www.RevBiosciences.com

.

.

Information for Stockholders

股东信息

Upon the effectiveness of the reverse stock split, each sixteen shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share.

反向股票分割生效后，公司已发行和流通的普通股每16股将自动合并并转换为一股已发行和流通的普通股。反向股票分割将统一影响所有股东，并且不会改变任何股东在公司股权中的相对权益，除非反向股票分割会导致股东持有部分股份。

Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded down to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock.

普通股持有人因反向股票分割而有权获得部分股份，因为他们持有的股份数量不能被反向股票分割比例平均分割，因此将四舍五入至最接近的整股。反向股票分割不会改变普通股的面值，也不会改变普通股的权利或偏好。

The Company’s transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records for the Company’s common stock. Registered stockholders holding pre-split shares of the Company’s common stock electronically in book-entry form are not required to take any action to receive post-split shares.

本公司的转让代理人大陆股票转让信托公司将保留本公司普通股的记账记录。以簿记形式以电子方式持有公司普通股预分割股份的注册股东无需采取任何行动来接收分割后的股份。

Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connect with the reverse stock split. Continental Stock Transfer & Trust Co.

通过经纪人、银行、信托或其他提名人持有股份的股东将根据该经纪人的特定流程自动调整其头寸，以反映反向股票分割，并且不需要采取任何与反向股票分割相关的行动。大陆股份转让信托公司。

can be reached at (212) 509-4000 or (800) 509-5586..

可拨打（212）509-4000或（800）509-5586。。

About Revelation Biosciences, Inc.

关于启示生物科学公司。

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation

启示生物科学公司是一家临床阶段生命科学公司，专注于利用其专有配方利用经过训练的免疫力来预防和治疗疾病

Gemini

双子座

. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

启示录有多个正在进行的项目来评估双子座，包括预防术后感染，预防急性肾损伤和治疗慢性肾脏疾病。

For more information on Revelation, please visit

有关启示的更多信息，请访问

www.RevBiosciences.com

www.RevBiosciences.com

.

.

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions.

本新闻稿包含1995年《私人证券诉讼改革法案》修订版中定义的前瞻性声明。前瞻性陈述是指不属于历史事实的陈述。这些前瞻性陈述通常由“预期”、“相信”、“预期”、“估计”、“计划”、“展望”和“项目”等类似表达来识别。

We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements.

我们提醒投资者，前瞻性陈述是基于管理层的预期，只是对当前预期的预测或陈述，涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果与前瞻性陈述所预期的结果大不相同。

Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regul.

《启示录》提醒读者不要过度依赖任何此类前瞻性声明，因为这些声明仅在发布之日起生效。除其他因素外，以下因素可能导致实际结果与这些前瞻性声明中描述的结果存在重大差异：由于竞争等原因，披露满足其财务和战略目标的能力；启示录增长和管理增长盈利能力并留住关键员工的能力；披露可能受到其他经济、业务和/或竞争因素不利影响的可能性；与启示录候选产品成功开发相关的风险；成功完成其候选产品的计划临床研究的能力；我们可能无法完全注册我们的临床研究或注册的风险将花费比预期更长的时间；与不良安全事件的发生和/或我们临床研究的数据或分析可能引起的意外问题有关的风险；适用法律或法规的变更。